{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:20Z","timestamp":1788153500911,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ovarian cancer (OC) is a biologically heterogeneous malignancy associated with poor clinical outcomes. Oncolytic viruses (OVs) have emerged as a promising immunotherapeutic strategy; however, optimal approaches to maximize their antitumor efficacy\u2014especially in combinatorial or sequential settings\u2014remain insufficiently defined. To determine how the sequence of administration of two clinically relevant, stem cell\u2013delivered OV platforms influences tumor control and immune remodeling in an immunocompetent OC model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated the sequence of two clinically relevant products: neural stem cell delivered conditionally replication competent adenovirus (NSC.CRAd-S-pk7; NNV24) and a mesenchymal stem cell delivered vaccinia virus (MSC.VP001; SNV1). Female C57BL\/6 mice were randomized into three groups: untreated tumor-bearing controls, NNV24 followed by SNV1 (NNV24+SNV1), or SNV1 followed by NNV24 (SNV1+NNV24). Therapeutic efficacy and immune responses were assessed by overall survival, histopathological evaluation, flow cytometric analysis of dendritic cell (DC) subsets and cytotoxic T lymphocytes (CTLs), and bulk RNA sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment regimens initiated with NNV24 significantly prolonged survival compared with SNV1-first sequences. NNV24+SNV1 treatment resulted in enhanced intratumoral viral localization, increased infiltration of CTLs, mature DCs, and concomitant with a reduction in tolerogenic DC populations. Transcriptomic profiling corroborated these findings through revealing suppression of immunoregulatory and tolerogenic pathways signaling in comparison to SNV1+NNV24 group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The treatment sequence of heterologous OV has a significant effect on the tumor microenvironment. NNV24+SNV1 promotes robust antitumor immunity and improved survival, whereas the reverse sequence compromises immune activation and therapeutic response. These findings establish a mechanistic framework for rational sequencing of OV-based immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1898617","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:28:11Z","timestamp":1788150491000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment sequence of stem cell delivered heterologous oncolytic virus impact on tumor microenvironment in immunocompetent ovarian cancer model"],"prefix":"10.3389","volume":"17","author":[{"given":"Eslam E.","family":"Abd El-Fattah","sequence":"first","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Flores","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Lara","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Ngai","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Mooney","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Aboody","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.21203\/rs.3.rs-6873532\/v1","article-title":"Global, regional, and national burden of ovarian cancer in women aged 45\u2009+\u2009from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 global burden of disease study","volume":"151","author":"Ren","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031845","article-title":"Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements","volume":"25","author":"Tavares","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/go.23.00393","article-title":"Global incidence of ovarian cancer according to histologic subtype: a population-based cancer registry study","volume":"10","author":"Wang","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246320","article-title":"Multiple treatment cycles of neural stem cell delivered oncolytic adenovirus for the treatment of glioblastoma","volume":"13","author":"Batalla-Covello","year":"2021","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142324","article-title":"Vaccinia virus-a swiss army knife against cancer","volume":"17","author":"Stawowczyk","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012934","article-title":"Neural stem cell-delivered oncolytic virus via intracerebroventricular administration enhances glioblastoma therapy and immune modulation","volume":"13","author":"Chai","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146900","article-title":"Systemic delivery strategies for oncolytic viruses: advancing targeted and efficient tumor therapy","volume":"26","author":"Xia","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.100","article-title":"Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma","volume":"19","author":"Ahmed","year":"2011","journal-title":"Mol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omto.2020.05.005","article-title":"Enhanced delivery of oncolytic adenovirus by neural stem cells for treatment of metastatic ovarian cancer","volume":"12","author":"Mooney","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.16-0204","article-title":"Systemically infused mesenchymal stem cells show different homing profiles in healthy and tumor mouse models","volume":"6","author":"Xie","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3892\/ol.2021.12499","article-title":"Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy","volume":"21","author":"Wang","year":"2021","journal-title":"Oncol Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113822","article-title":"Formulation-optimized oncolytic viruses: advancing systemic delivery and immune amplification","volume":"383","author":"Ma","year":"2025","journal-title":"J Controlled Release"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142296","article-title":"Cell carriers for oncolytic virus delivery: prospects for systemic administration","volume":"17","author":"Sarkisova","year":"2025","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.002","article-title":"Oncolytic virotherapy: single cycle cures or repeat treatments? (repeat dosing is crucial!)","volume":"26","author":"Melcher","year":"2018","journal-title":"Mol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.003","article-title":"For the success of oncolytic viruses: single cycle cures or repeat treatments? (one cycle should be enough)","volume":"26","author":"Russell","year":"2018","journal-title":"Mol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.9b01523","article-title":"Heterologous prime-boost enhances the antitumor immune response elicited by plant-virus-based cancer vaccine","volume":"141","author":"Cai","year":"2019","journal-title":"J Am Chem Soc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100209","article-title":"Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack","volume":"2","author":"Bonilla","year":"2021","journal-title":"Cell Rep Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-547-7_32","article-title":"Immunocompetent mouse model of ovarian cancer for in vivo imaging","volume":"1049","author":"Nunez-Cruz","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/path.4002","article-title":"The peritoneal tumour microenvironment of high-grade serous ovarian cancer","volume":"227","author":"Leinster","year":"2012","journal-title":"J Pathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13287-021-02226-8","article-title":"Allogeneic human neural stem cells for improved therapeutic delivery to peritoneal ovarian cancer","volume":"12","author":"Mooney","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246136","article-title":"Development of allogeneic stem cell-based platform for delivery and potentiation of oncolytic virotherapy","volume":"14","author":"Nguyen","year":"2022","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2013-0039","article-title":"The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma","volume":"2","author":"Tobias","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11.4.1","DOI":"10.1002\/0471250953.bi1114s51","article-title":"Mapping RNA\u2010seq reads with STAR","volume":"51","author":"Dobin","year":"2015","journal-title":"Curr Protoc Bioinf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00245-x","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed Malignant glioma: a first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12967-019-1829-z","article-title":"Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers","volume":"17","author":"Draganov","year":"2019","journal-title":"J Transl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/hum.2007.002","article-title":"Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma","volume":"18","author":"Ulasov","year":"2007","journal-title":"Hum Gene Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_00000199","article-title":"Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy","volume":"34","author":"Ulasov","year":"2009","journal-title":"Int J Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2012.21","article-title":"Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model","volume":"19","author":"Thaci","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.omto.2022.09.003","article-title":"Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer","volume":"27","author":"Araki","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2012.21","article-title":"Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection1","volume":"62","author":"Miller","year":"2002","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00262-024-03849-5","article-title":"Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity","volume":"74","author":"Ohtani","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01190-07","article-title":"Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses","volume":"81","author":"Waibler","year":"2007","journal-title":"J Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003989","article-title":"Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS\/STING-mediated cytosolic DNA-sensing pathway","volume":"10","author":"Dai","year":"2014","journal-title":"PloS Pathog"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045840","article-title":"Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens","volume":"7","author":"Ratto-Kim","year":"2012","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2020-6542","article-title":"Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects","volume":"80","author":"Nguyen","year":"2020","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.05.014","article-title":"A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses","volume":"32","author":"Rojas","year":"2024","journal-title":"Mol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1324744","article-title":"Oncolytic vaccinia virus and cancer immunotherapy","volume":"14","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8000","article-title":"Oncolytic adenovirus: a tool for reversing the tumor microenvironment and promoting cancer treatment (review)","volume":"45","author":"Wang","year":"2021","journal-title":"Oncol Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00251-y","article-title":"Metabolic reprogramming in macrophage responses","volume":"9","author":"Liu","year":"2021","journal-title":"biomark Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34139","article-title":"Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy","volume":"151","author":"Wang","year":"2022","journal-title":"Int J Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840029","article-title":"Metabolic reprogramming induces macrophage polarization in the tumor microenvironment","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.082","article-title":"Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus","volume":"36","author":"Jung","year":"2018","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1898617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:28:12Z","timestamp":1788150492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1898617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2026.1898617"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1898617","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1898617"}}